Phathom Pharmaceuticals (PHAT) Profit After Tax (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Profit After Tax for 9 consecutive years, with -$17.6 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Profit After Tax rose 76.81% year-over-year to -$17.6 million; the TTM figure through Jun 2026 stood at -$99.1 million (up 69.99% YoY), while the FY2025 annual figure was -$221.2 million, up 33.82% from the prior year.
• Profit After Tax grew to -$17.6 million in Q2 2026 per PHAT's latest filing, from -$30.4 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$17.6 million in Q2 2026 and bottomed at -$94.3 million in Q1 2025.
• Historically, Profit After Tax has averaged -$55.7 million across 5 years, with a median of -$51.0 million in 2022.
• Annual changes were most pronounced in 2024 — Profit After Tax tumbled 123.23% — and 2026, when it surged 76.81%.
• Phathom Pharmaceuticals' Profit After Tax stood at -$55.0 million in 2022, then sank by 44.55% to -$79.6 million in 2023, then rose by 6.43% to -$74.5 million in 2024, then jumped by 71.59% to -$21.1 million in 2025, then rose by 16.86% to -$17.6 million in 2026.
• Business Quant data shows PHAT's Profit After Tax at -$17.6 million in Q2 2026, -$30.4 million in Q1 2026, and -$21.1 million in Q4 2025.